Brief: Galmed Announces Positive Results From First 16 Patients In Open-Label Part Of Armor Study

Eocene

01/11/2021 14:13

Nov 1 (Reuters) - Galmed Pharmaceuticals Ltd  GLMD.O :
    * GALMED ANNOUNCES POSITIVE RESULTS FROM FIRST 16 PATIENTS
IN
OPEN-LABEL PART OF ARMOR STUDY
    * GALMED - TREATMENT WITH ARAMCHOL 300MG BID REDUCED
FIBROSIS
PROGRESSION MEASURED BY HISTOLOGY IN 15 OUT OF 16 PATIENTS
COMPLETED AS OF DATA CUTOFF
    * GALMED PHARMACEUTICALS LTD - 50% OF 16 PATIENTS SHOWED
FIBROSIS
IMPROVEMENT BY ≥1 STAGE, SEEN AS EARLY AS 24 WEEKS

Source text for Eikon:  urn:newsml:reuters.com:*:nPn3sRRmSa
Further company coverage:  GLMD.O 

 ((Reuters.Briefs@thomsonreuters.com;))